Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis
Graham Lohrmann(Boston University), Frederick L. Ruberg(Boston University), Roberta Mussinelli, Lawreen H. Connors(Boston University), Deepa M. Gopal(Boston University), Nirupama Vellanki(Boston University), John L. Berk(Boston University), Matthew J. Maurer(Mayo Clinic in Arizona), Jennifer Hellawell(Amgen (United States)), Omar K. Siddiqi(Boston University), Alexandra Pipilas(Boston University), Jonathan C. Fox(Fluidigm (United States))
Cited by 106
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k